Novel, redosable in vivo CAR platform for reprogramming multiple immune cell types against solid tumors
11 Feb 2026
Theatre 1
Technology and Innovation
The design and application of a novel in vivo chimeric antigen receptor (CAR) system capable of reprogramming diverse immune cell populations. Participants will gain insights into platform engineering, dosing strategies, and translational considerations for solid tumor therapies, with a focus on enhancing therapeutic reach and adaptability.
Key takeaways:
- Understand the principles of redosable in vivo CAR platform design.
- Explore strategies for targeting multiple immune cell types in solid tumors.
- Learn approaches to optimize dosing, efficacy, and safety.
- Apply insights into translational development for preclinical and clinical studies.
- Gain perspectives on platform adaptability and therapeutic precision.
